

## CordLife Sciences India Pvt. Ltd.

P.L. Deuty Road Bishnupur 24 Pgs. (S) West Bengal 743 503  
Ph: 91-33-2480 9565 • Fax: 91-33-2480 9566  
E-mail: info@cordlifeindia.com • www.cordlifeindia.com



### Media Advisory: For Immediate Release

## CordLife's Business Expansion Brings Hope to Diabetic Patients in India

- CordLife puts India in the world map with the latest world advanced umbilical cord banking technology.
- The technology has the unique ability to isolate two cell types which may be used to repair injured tissues/organs and induce faster healing of diabetic foot ulcers as well as other injuries.
- CordLife is in the initial stages of identifying prominent institutions and specialist physicians in India to conduct the application of umbilical cord stem cells on patients with diabetic ulcers.

**Kolkata, 4<sup>th</sup> November 2009** – CordLife, Asia Pacific's largest network of stem cell banks, officially launched the most advanced umbilical cord banking technology in India. This technology has the unique ability to isolate two cell types to help hasten the healing of general and diabetic foot ulcers or repair injured tissues and organs.

The Asia Pacific stem cell banking leader will provide the collection and storage of umbilical cord stem cells as a value-added service for all their cord blood banking customers over a limited time. Unlike conventional technology, that can only isolate mesenchymal stem cells, the advanced technology can isolate both mesenchymal and epithelial stem cells from the umbilical cord. When used in conjunction with cord blood or bone marrow stem cells, mesenchymal stem cells could increase the success rate of a transplant. They also have immense potential to treat diseases and repair injured tissues or organs.

Epithelial stem cells have the potential to rejuvenate skin and mucus membranes to treat non-healing wounds, especially that of patients with diabetic ulcers. The company is now in the initial stage of identifying prominent institutions and specialist physicians to provide the application of epithelial stem cells on diabetic patients.

“As an international stem cell bank, it is important for us to facilitate cellular therapy opportunities and bring these opportunities to families in India. With approximately 40.9 million people in India diagnosed with diabetes and 1 in every 6 of them estimated to have an ulcer during their lifetime, CordLife's umbilical cord banking technology will help to harvest the right and important stem cells that may prevent amputations,” said Mr Steven Fang, Group CEO, CordLife Ltd.

“Typically, diabetic ulcers are very difficult to heal. With epithelial stem cells, the ulcers can be healed within 45 days.” added Mr. Meghnath Roy Chowdhury, Managing Director, CordLife Sciences India Pvt. Ltd.

The Australian Securities Exchange listed company reported a consolidated group revenue and net profit of over 100 crores (A\$23,686,000) and 18 crores (A\$4,224,000) for the year ended 30 June 2009, a year on year increase of 60 per cent and 1,731 per cent respectively. Within a few months from its official launch this year, the company achieved market leadership in Eastern India. They have also established in most parts of Northern India. Plans are underway to establish offices throughout India within the next nine months.



### **About CordLife Sciences (India)**

CordLife Sciences India Pvt. Ltd is a subsidiary of CordLife Ltd. The Company obtained its operating license in 2008 from the Central and state drug regulatory authorities, part of the Ministry of Health and Family Welfare of India. The latest and the most advanced addition to the CordLife network, this Kolkata facility is the largest in India, with storage capacity of up to 150,000 cord blood units. The ISO certified 20,000 sq. ft. facility was built following the latest international standards such as the American Association of Blood Banks (AABB).

### **About CordLife Group**

CordLife operates Asia Pacific's most experienced and largest network of stem cell banks with full processing and cryopreservation storage facilities in Singapore, Australia, Hong Kong, Indonesia and India as well as marketing operations in Macau, Philippines and Thailand. The Group's in-depth knowledge of stem cell banking practices and standards are recognised by many international Quality Standard organizations such as the American Association of Blood Banks (AABB), Therapeutic Goods Administration (TGA) and International Organisation for Standardisation (ISO). The Group and its associate companies have a track record of providing stem cells for more than 100 successful transplants and applications. CordLife was recently appointed as a Quality Consultant to assist Beijing China Cord Blood Bank, one of the largest stem cell banks in China. In 2006, CordLife became the only stem cell bank in the world to be awarded the prestigious World Economic Forum 'Technology Pioneer'. CordLife is listed on the Australian Securities Exchange, under the stock code; CBB. For more information on the CordLife group of companies, please visit [www.cordlife.com](http://www.cordlife.com).

For further information please contact:

#### **Candid Communication**

Paromita Ghosh / Sushmita Mukherjee  
9830213398 / 9836466361

#### **CordLife Sciences India Pvt. Ltd.**

Jamie Woon / Sreya Roy Bose  
+65 9772 9391 / 9830665900  
[jamie.woon@cordlife.com](mailto:jamie.woon@cordlife.com) / [sreya@cordlifeindia.com](mailto:sreya@cordlifeindia.com)

#### **CordLife Limited**

Steven Fang  
Group CEO  
+65 6238 0808 / +65 9739 8883  
[sfang@cordlife.com](mailto:sfang@cordlife.com)